Deals get done Deals between Canadian based company and big asian/ global companies gets done so THTX oncology program can attract partners globally. Genevant has offices in BC Canada, US and Switzerland.
https://www.genevant.com/contact-us/
“Under the terms of the deal, Genevant will receive as much as $303 million in upfront and possible milestone payments, plus royalties on future sales. Takeda will have exclusive access to the former's LNP technology in all phases of development and distribution. Neither of the companies revealed the two types of liver diseases they are targeting with this project.”
Genevant, Takeda Enter Collab to Find a Cure for Rare Liver Diseases | BioSpace
As per their LNP technology:
“LNPs can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of nucleic acid payloads to target tissues.”
Their first collaboration March 2021:
“Under the terms of the agreement, Genevant is initially eligible to receive up to $600 million in upfront and milestone payments, plus royalties on future product sales. Takeda has exclusive rights to Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets.”
https://finance.yahoo.com/amphtml/news/genevant-sciences-announces-global-collaboration-120000465.html